CollPlant Biotechnologies Q3 2024 Adj EPS $(0.33) Misses $(0.28) Estimate, Sales $4.00K May Not Be Comparable To $416.00K Estimate
CollPlant Biotechnologies Q3 2024 Adj EPS $(0.33) Misses $(0.28) Estimate, Sales $4.00K May Not Be Comparable To $416.00K Estimate
collplant生物技术2024年第三季度调整后的每股收益为$(0.33)，低于$(0.28)的预期，销售额为$0.4万，可能无法与$41.6万的预期相比较。
CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.28) by 17.86 percent. This is a 5.71 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $4.00 thousand which missed the analyst consensus estimate of $416.00 thousand by 99.04 percent. This is a 90.70 percent decrease over sales of $43.00 thousand the same period last year.
CollPlant Biotechnologies（纳斯达克股票代码：CLGN）公布的季度亏损为每股0.33美元，比分析师普遍预期的0.28美元（0.28美元）低17.86％。这比去年同期每股亏损0.35美元（0.35美元）增长了5.71％。该公司公布的季度销售额为40万亿美元，比分析师普遍预期的41.6万美元低99.04％。这比去年同期的43,000美元销售额下降了90.70％。
热门讨论
美联储暂停降息，你如何调整持仓？
美联储宣布基准利率维持在4.25%—4.50%不变，符合市场预期。你会如何配置资产？
Moo Live
01/30 03:25
联邦公开市场委员会新闻发布会，2025年1月29日